CAS No 1446321-46-5 Voxelotor Pharmaceutical Intermediates-1

-INNOVATIVE THERAPY:Voxelotor is a breakthrough therapeutic designed to improve hemoglobin function in patients with sickle cell disease.
-Enhanced Efficacy:Shows significant improvements in hemoglobin levels and reduces the frequency of sickle cell crises.
-Safety:Voxelotor has a good safety profile with minimal side effects,supported by extensive clinical trials.
-Manufacturing Excellence:Produced in state-of-the-art equipment ensuring the highest quality standards and compliance with pharmaceutical regulations.
-Integrated Supply Chain:As a production and trading integrated factory,we guarantee timely delivery and competitive prices.

product details

Product details

Product detail

Voxelotor is a novel therapeutic designed to treat sickle cell disease(SCD).The disease is characterized by abnormally shaped red blood cells and can lead to a variety of complications,including episodes of severe pain and organ damage.Voxelotor works by increasing hemoglobin levels in the blood,thereby reducing sickling of red blood cells and improving overall blood flow.This innovative approach not only relieves symptoms but also addresses the root cause of the disease.

product detail

Product name	Voxelotor
CAS No.	1446321-46-5
EINECS	/
Formula	C19H19N3O3
Molecular Weight	337.37
Appearance	White to Off-White solid
Purity	≥98%
Type	Pharmaceutical Intermediates

Physical and chemical properties

Voxelotor is a small molecule with unique physical and chemical properties that makes it an effective treatment option for SCD.Its molecular structure allows it to optimally bind to hemoglobin,thereby enhancing its stability and functionality.The compound is soluble in water,allowing for easy administration and in vivo absorption.

-Molecular formula:C19H22N4O3S

-Molecular Weight:378.47 g/mol

-Solubility:High solubility in aqueous solutions ensuring rapid bioavailability.

-STABILITY:Demonstrates excellent stability under various storage conditions,ensuring product integrity over time.

These properties help Voxelotor effectively increase hemoglobin levels and reduce the incidence of vaso-occlusive crisis,a common complication in patients with sickle cell disease.

Advantages

1.Improved Quality of Life:Clinical studies show that patients treated with Voxelotor experience reduced pain crises and improved overall health,thereby improving quality of life.
2.Reduced Hospitalizations:By effectively controlling symptoms and preventing complications,Voxelotor can significantly reduce the need for doctor visits and emergency intervention.
3.Convenient Dosing:Voxelotor comes in an easy-to-administer oral formulation,making it easy for patients to integrate into their daily lives.
4.Comprehensive Support:Our company offers extensive support to healthcare professionals and patients,including educational resources and patient assistance programs.
5.Quality Commitment:As a factory integrating production and trade,we adhere to strict quality control measures throughout the entire manufacturing process.Our facilities are equipped with advanced technology and staffed by experienced professionals dedicated to producing high-quality pharmaceutical products.
6.Regulatory Compliance:Voxelotor is manufactured in compliance with all relevant regulatory standards,ensuring the highest safety and effectiveness benchmarks are met.

In summary

Voxelotor represents a major advance in the treatment of sickle cell disease,giving patients new hope in managing their disease.With its unique physical and chemical properties,proven efficacy and commitment to quality,Voxelotor is poised to make a lasting impact in the pharmaceutical industry.Our combined manufacturing and trading capabilities ensure we can deliver this innovative treatment to healthcare providers and patients efficiently and reliably.Choose Voxelotor for a brighter future in sickle cell disease management.